Mirati To Present Research at the AACR Annual Congress for Two Potentially First-in-Class Clinical Stage Programs

Rhea-AI Summary

Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced significant preclinical findings for its targeted oncology treatments, MRTX0902 and MRTX1719. The data, to be presented at the AACR 2023 Annual Congress on April 17, shows that MRTX0902, a selective SOS1 inhibitor, enhances anti-tumor efficacy in combination with KRAS^G12C and EGFR inhibitors. This presentation is scheduled for 3:36 p.m. ET. Additionally, MRTX1719's mechanism for inducing synthetic lethality in MTAP deleted tumors will be showcased in poster presentations from 1:30 p.m. - 5:00 p.m. ET.

Preclinical data highlights MRTX0902 and MRTX1719 as potentially compelling targeted oncology treatment options

SAN DIEGO, April 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced a presentation demonstrating in preclinical models the ability of MRTX0902, a selective and potent SOS1 inhibitor, to enhance anti-tumor activity and overcome acquired resistance in combination with either adagrasib, a potent and selective KRAS^G12C inhibitor, or an epidermal growth factor receptor (EGFR)  inhibitor (e.g. osimertinib).

Findings will be presented on April 17 at the American Association for Cancer Research (AACR 2023) Annual Congress as an oral presentation at 3:36 p.m. -3:51 p.m. ET / 12:36 p.m.- 12:51 p.m. PT (Presentation #3499) during the Molecular Pathway Discovery and Translation in Solid Tumors mini session. The full abstract for the presentation can be found here.

In addition, Mirati will share poster presentations featuring MRTX1719, the company's novel MTA cooperative PRMT5 inhibitor. These posters highlight the mechanism by which MRTX1719 elicits potent and selective synthetic lethality in MTAP deleted tumors as well as the further enhancement of antitumor activity via rational targeted combination strategies (Posters #2778/1 and 2779/2). Posters can be viewed on April 17 from 1:30 p.m. - 5:00 p.m. ET/ 10:30 a.m. - 2:00 p.m. PT during the Experimental and Molecular Therapeutics Session and will be available here.

About Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc. is a commercial stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer.

For more information about Mirati, visit us at Mirati.com or follow us on Twitter, LinkedIn and Facebook. 

Forward Looking Statements

This press release includes forward-looking statements regarding Mirati's business, financial guidance and the therapeutic and commercial potential of KRAZATI^® (adagrasib), sitravatinib (TAM receptor inhibitor), MRTX1719 (MTA-cooperative PRMT5 inhibitor), MRTX0902 (SOS1 inhibitor), and MRTX1133 (selective KRASG12D inhibitor), Mirati's technologies and Mirati's other products in development. Any statement describing Mirati's goals, expectations, intentions or beliefs, financial or other projections, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines.

Mirati's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Mirati's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Mirati. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Mirati's programs are described in additional detail in Mirati's annual report on Form 10-K, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission and available at the SEC's Internet site (www.sec.gov). These forward-looking statements are made as of the date of this press release, and Mirati assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Mirati Contacts
Investor Relations: ir@mirati.com
Media Relations: media@mirati.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/mirati-to-present-research-at-the-aacr-annual-congress-for-two-potentially-first-in-class-clinical-stage-programs-301788788.html

SOURCE Mirati Therapeutics, Inc.

FAQ

What are the key findings from the Mirati press release regarding MRTX0902?

The press release highlights that MRTX0902, a selective SOS1 inhibitor, enhances anti-tumor activity and overcomes resistance when combined with KRAS^G12C or EGFR inhibitors.

When will Mirati present its research findings at the AACR Annual Congress?

Mirati will present its findings on April 17, 2023.

What is MRTX1719 and what does the press release say about it?

MRTX1719 is a novel MTA cooperative PRMT5 inhibitor, and the press release discusses its ability to induce synthetic lethality in MTAP deleted tumors.

What time is the presentation for MRTX0902 at AACR 2023?

The presentation for MRTX0902 is scheduled for 3:36 p.m. - 3:51 p.m. ET on April 17, 2023.

Where can I find more information about Mirati's research presented at AACR 2023?

More information, including abstracts and posters, can be accessed via links provided in the press release.